KG LEGAL \ INFO
BLOG

Artificial Intelligence in Healthcare: the Risks Behind the Promise

Publication date: November 04, 2026

Errors, bias, opacity, data security and the accountability gap – what patients, clinicians and regulators need to watch

Artificial intelligence is already reading scans, ranking medical literature, predicting kidney failure and managing hospital beds. Its potential to make medicine faster, more precise and more personalised seems almost limitless. Yet the same technology brings a distinct set of risks: algorithms that fail silently, tools used without adequate training, models that reproduce existing inequalities, decisions that no one can explain, patient data that is exposed or re-used, and a legal framework that still struggles to say who is responsible when something goes wrong. This article maps those risks and outlines what is needed to manage them.

More

A Purchased Innovation Is Not R&D. When Do AI Projects Qualify for the Polish R&D Tax Relief?

Publication date: November 02, 2026

A growing number of businesses are investing in artificial intelligence and expect to recover the cost of those projects through the research and development (R&D) tax relief. The Polish tax authorities and the Supreme Administrative Court, however, draw a clear line: integrating an off-the-shelf AI model or implementing a commercially available system – however advanced or “self-learning” – is not R&D activity. The relief is available only to those who create new technology themselves and bear genuine research risk. We explain how the tax authorities’ “two-step test” works, what the Frascati Manual and the case law of the Supreme Administrative Court say, which costs in IT projects qualify and which are traps – and how to document the work so that the deduction survives a tax audit.

More

A Human in the Loop, Data under Control. The GDPR and the AI Act in Implementation Practice

Publication date: October 05, 2026

Implementing artificial intelligence in an organisation does not begin with choosing a tool, but with answering the question of who we are in the AI value chain and what we are responsible for. This article sets out the relationship between the GDPR and the AI Act: from the roles of provider, deployer and controller, through algorithmic risks, the limits of lawfulness in the workplace and the rights of individuals, to the DPIA, the FRIA and the AI Governance model. It reflects the legal position following the entry into force of the Polish Act on Artificial Intelligence Systems and the postponement of the AI Act application dates by Regulation (EU) 2026/1744.

More

LEGAL ASPECTS OF THE USE OF ML AND AI IN PHARMACEUTICAL PRODUCTION – POLISH AND EU REGULATIONS

Publication date: January 16, 2026

Pharmaceutical production is one of the most regulated activities in Poland, Europe, and globally. The reason seems obvious: creating drugs can cause numerous complications, health problems, and in extreme cases, even death, depending on the individual patient’s health contraindications. Due to the above-mentioned reasons, the process of creating a new drug is often very expensive and lengthy, and involves a large number of professionals and scientists specializing in this field. In an era of dynamic digitalization, the need to develop specific operational rules for drug production and principles for using AI (Artificial Intelligence) and ML (Machine Learning) models is increasingly emphasized. Manufacturers are often considering implementing AI systems to support pharmaceutical production processes.

More

UP